June 2, 2014 News by Charles Moore Genzyme Resubmits Multiple Sclerosis Drug Lemtrada For FDA sBLA Approval Review Cambridge, Mass. Based Genzyme, a Sanofi subsidiary, announced May 30 that the U.S. Food and Drug Administration (FDA) has accepted for review the companyās resubmission of its supplemental Biologics License Application (sBLA) seeking approval of its proprietary drug Lemtrada (alemtuzumab) for treatment of relapsing forms of multiple sclerosis (MS).
May 7, 2014 News by Charles Moore Genzyme Enters Multi-Year MS Research Collaboration with Cleveland Clinic’s Academic Medical Center Cambridge, Massachusetts based biotech firm GenzymeĀ has formed a new research collaboration with Cleveland Clinic of Cleveland, Ohio with a focus on developing new therapeutic approaches to the treatment of Multiple Sclerosis (MS). More than 2.3 million people worldwide have been diagnosed with MS, including what is believed…